Vivos Inc. (RDGL)

OTCMKTS · Delayed Price · Currency is USD
0.0849
+0.0001 (0.12%)
At close: Feb 27, 2026
-23.51%
Market Cap 38.68M
Revenue (ttm) 48.62K
Net Income (ttm) -3.01M
Shares Out 455.54M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 93,577
Average Volume 571,282
Open 0.0836
Previous Close 0.0848
Day's Range 0.0823 - 0.0849
52-Week Range 0.0425 - 0.1657
Beta -0.59
RSI 64.60
Earnings Date Feb 27, 2026

About Vivos

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. The company develops an yttrium-90 based precision radionuclide therapy device; RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing a universal laboratory cooling device; hydrogel; and other products under the Alpha-Gel, Beta-... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1994
Employees 1
Stock Exchange OTCMKTS
Ticker Symbol RDGL
Full Company Profile

Financial Performance

In 2024, Vivos's revenue was $27,995, an increase of 43.56% compared to the previous year's $19,500. Losses were -$2.91 million, 0.54% more than in 2023.

Financial Statements

News

There is no news available yet.